<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967497</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02-003C</org_study_id>
    <nct_id>NCT02967497</nct_id>
  </id_info>
  <brief_title>Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type</brief_title>
  <official_title>An Open Label Study of UanQiHuoLi Tang Plus Cisplatin-based Chemotherapy in Advanced Epidermal Growth Factor Receptor Wild Type Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Yang Ming University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot phase II trial studies the effect of YQ1, a herbal medicine, with&#xD;
      cisplatin-based chemotherapy on gut microbiota and immune response in patients with EGFR/ALK&#xD;
      wild type non-small cell lung cancer, stage IIIB-IV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized pilot phase II trial studies the effect of YQ1, a herbal medicine, with&#xD;
      cisplatin-based chemotherapy on gut microbiota and immune response in patients with EGFR/ALK&#xD;
      wild type non-small cell lung cancer, stage IIIB-IV. Chinese herbal medicine was known to be&#xD;
      beneficial adjuvant or alternative medicine for cancer treatment. However, the mechanism was&#xD;
      unknown. This study wants to investigate the effect and mechanism of YQ1, which was proved to&#xD;
      improve the antitumor immunity, to inhibit cancer progression, and to prolong overall&#xD;
      survival of lung adenocarcinoma in a series of preclinical studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Blank</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention, just observation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YQ1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin-based chemotherapy + YQ1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YQ1</intervention_name>
    <description>Oral administered powder</description>
    <arm_group_label>YQ1 group</arm_group_label>
    <other_name>a herbal medicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is&#xD;
             advanced/metastatic (stage IIIB/IV), EGFR/ALK wild type.&#xD;
&#xD;
          -  Subjects who plan to receive cisplatin-based chemotherapy.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign an Institutional Review Board&#xD;
             (IRB)-approved informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status &gt;= 3&#xD;
&#xD;
          -  WBC =&lt; 4,000 cells/Î¼l, ANC =&lt; 1,500/mcL, Platelets =&lt; 100,000/mcL , Hemoglobin =&lt; 9&#xD;
             g/dL,&#xD;
&#xD;
          -  Total bilirubin &gt;= 1.5 x upper limit of normal (ULN), AST &gt;= 1.5x ULN, ALT &gt;= 2.5 x&#xD;
             ULN, Creatinine &gt;= 1.5x ULN&#xD;
&#xD;
          -  Current uncontrolled cardiac disease such as angina or myocardial infarction,&#xD;
             congestive heart failure.&#xD;
&#xD;
          -  Chronic or current Inflammatory Bowel Disease, post-surgery of intestine, Lynch&#xD;
             syndrome, FAP, Peutz-Jegher.&#xD;
&#xD;
          -  History of allergic reactions cisplatin&#xD;
&#xD;
          -  Pregnant women are excluded; breastfeeding should be discontinued prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Received any other clinical trail at the same time.&#xD;
&#xD;
          -  Current dementia or other cognitive disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2016</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <keyword>Herbal medicine</keyword>
  <keyword>Lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

